Lilly gets USFDA nod for Taltz(ixekizumab) for Pediatric Patients with Moderate to Severe Plaque Psoriasis Medical Dialogues Bureau1 April 2020 7:00 AM GMTIndianapolis: Eli Lilly and Company have announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental Biologics License Appli...
Eli Lilly delays its clinical trials during Coronavirus pandemic Medical Dialogues Bureau25 March 2020 9:30 AM GMTIndianapolis: Eli Lilly and Company has provided an update on the company's clinical trial activities in light of the COVID-19 pandemic. The company wi...
Lilly Receives FDA Breakthrough Therapy Designation for Baricitinib for Alopecia Areata Medical Dialogues Bureau19 March 2020 7:26 AM GMTBaricitinib is currently approved for the treatment of adults with moderately to severely active rheumatoid arthritis (RA).
AbCellera, Eli Lilly join hands for Antibody Therapies for COVID-19 Medical Dialogues Bureau13 March 2020 3:30 AM GMTVancouver and Indianapolis: AbCellera and Eli Lilly and Company have recently announced that they have entered into an agreement to co-develop...
USFDA accepts regulatory submission for tanezumab for management of chronic pain due to osteoarthritis Medical Dialogues Bureau7 March 2020 4:30 AM GMTTanezumab is a monoclonal antibody that is part of an investigational class of non-opioid chronic pain medications known as nerve growth factor (NGF)...
FDA Advisory approves Lilly's CYRAMZA (ramucirumab) for type of lung Cancer Medical Dialogues Bureau1 March 2020 8:30 AM GMTThe ODAC considered the safety and efficacy data from the Phase 3 RELAY trial, which is the basis for the CYRAMZA supplemental Biologics License...
